The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3825-3833

  Kankuri, Minna ^a   Söderström, Karl Ove ^a   Pelliniemi, Tarja Terttu ^a   Vahlberg, Tero ^b   Pyrhönen, Seppo ^a   Salminen, Eeva ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b TURKU UNIVERSITY   (Finland)

Author keywords

Heidelberg classification; Ki 67; p53; Renal carcinoma; T stage

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 33750726054     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Mathew A, Devesa SS, Fraumeni JF Jr and Chow WH: Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 11: 171-178, 2002.
2. Yuan JM, Castelao JE, Gago-Dominguez M, Ross RK and Yu MC: Hypertension, obesity and their medications in relation to renal cell carcinoma. Br J Cancer 77: 1508-1513, 1998.
3. Janzen NK, Kim HL, Figlin RA and Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30: 843-852, 2003.
4. McNichols DW, Segura JW and DeWeerd JH: Renal cell carcinoma: Long-term survival and late recurrence. J Urol 126: 17-22, 1981.
5. Pyrhönen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P and Kellokumpu-Lehtinen PL: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859-2867, 1999.
6. Kankuri M, Pelliniemi TT, Pyrhönen S, Nikkanen V, Helenius H and Salminen E: Feasibility of prolonged use of interferon-a in metastatic kidney carcinoma. A phase II study. Cancer 92: 761-767, 2001.
7. Spanknebel K, Cheung KY, Stoutenburg J, Hurst-Wicker K, Hesdorffer C, Rn GD and Kaufman AH: Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2. Ann Surg Oncol 12: 381-390, 2005.
8. Mickisch GH, Garin A, van Poppel H, de Prijck L and Sylvester R: European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966-970, 2001.
9. Tsui KH, Shvarts O, Smith RB, Figlin RA, de Kernion JB and Belldegrun A: Prognostic indicators for renal cell carcinoma. A multivariate analysis of 643 patients using revised 1997 TNM staging criteria. J Urol 163: 1090-1095, 2000.
10. Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, Ecke M, Woltjen HH, Jentsch H, Wieland W, Wandert T and Reitz M: German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (DGCIN). Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92: 843-846, 2005.
11. Repmann R, Goldschmidt AJ and Richter A: Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Anticancer Res 23: 969-974, 2003.
12. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A and Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540, 1999.
13. Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663, 1982.
14. Delahunt B, Kittelson JM, McCredie MR, Reeve AE, Stewart JH and Bilous AM: Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters. Cancer 94: 658-664, 2002.
15. Kanamaru H, Akino H, Suzuki Y, Noriki Y, Noriki S and Okada K: Prognostic value of nuclear area index in combination with the World Health Organization grading system for patients with renal cell carcinoma. Urology 57: 257-261, 2001.
16. Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G and Novick A: TNM staging of renal cell carcinoma: Workgroup No.3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80: 992-993, 1997.
17. Sobin L and Wittekind C: TNM Classification of Malignant Tumors, 6th edition. John Wiley & Sons, 2002.
18. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Störkel S, van den Berg E and Zbar B: The Heidelberg classification of renal cell tumors. J Pathol 183: 131-133, 1997.
19. de la Taille A, Buttyan R, Katz AE, McKiernan J, Burchardt M, Buchardt T, Chopin DK and Sawczuk IS: Biomarkers of renal cell carcinoma. Past and future considerations. Urol Oncol 5: 139-148, 2000.
20. Kankuri M, Sauroja I, Aho H, Pelliniemi TT and Salminen E: The expression of p53, pRb, p27 and Ki-67 in renal cell cancer. Abstract P306 in Abstracts Book of The 8th International Congress on Anti-Cancer Treatment, 1998.
21. Reich NC and Levine AJ: Growth regulation of a cellular tumor antigen, p53, in nontransformed cells. Nature 308: 199-201, 1984.
22. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M and Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539, 1988.
23. Choisy-Rossi C and Yonish-Rouach E: Apoptosis and the cell cycle: the p53 connection. Cell Death Differ 5: 129-131, 1998.
24. May P and May E: Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18: 7621-7636, 1999.
25. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
26. du Manoir S, Guillaud P, Camus E, Seigneurin D and Brugal G: Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment. Cytometry 12: 455-463, 1991.
27. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
28. Mostofi FK, Davis CJ in Collaboration with Sobin LH and Pathologists in 6 Countries World Health Organization. Histological typing of kidney tumors. In: International Histological Classification of Tumors (2nd ed). Berlin Heidelberg, Springer, pp. 1-117, 1998.
29. Olumi AF, Weidner N and Presti JC: P53 immunoreactivity correlates with Ki-67 and bcl-2 expression in renal cell carcinoma. Urol Oncol 6: 63-67, 2001.
30. Hosmer DW and Lemeshow S: Applied Logistic Regression; (2nd ed). New York, John Wiley & Sons Inc, pp. 1-375, 2000.
31. Tobe SW, Noble-Topham SE, Andrulis IL, Hartwick RW, Skorecki KL and Warner E: Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage. Clin Cancer Res 1: 1611-1615, 1995.
32. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
33. Nishitani MA, Sakai T, Ishii K, Zhang M, Nakano Y, Nitta Y, Miyazaki J, Kanayama HO, Kagawa S and Himeno K: A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells. Cancer Gene Ther 9: 156-163, 2002.
34. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8: 282-288, 2002.
35. Haitel A, Wiener HG, Baethge U, Marberger M and Susani M: mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res 6: 1840-1844, 2000.
36. Kirkali Z, Yorukoglu K, Ozkara E, Kazimoglu H and Mungan U: Proliferative activity, angiogenesis and nuclear morphometry in renal cell carcinoma. Int J Urol 8: 697-703, 2001.
37. Rioux-Leclercq N, Turlin B, Hansard J, Patard J, Manunta A, Moulinoux JP, Guille F, Ramee MP and Lobel B: Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urol 55: 501-505, 2000.
38. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC and Hainaut P: The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-614, 2002.
39. Zigeuner R, Ratschek M, Rehak P, Schips L and Langner C: Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 63: 651-655, 2004.
40. Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF and Williams GH: Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 11: 2510-2517, 2005.
41. Uchida T, Gao JP, Wang C, Jiang SX, Muramoto M, Satoh T, Minei S, Shimura S, Irie A, Kameya T and Baba S: Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 59: 615-620, 2002.
42. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A and Pantuck AJ: p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol 173: 725-728, 2005.
43. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Figlin RA, Horvath S and Belldegrun AS: Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10: 5464-5471, 2004.
44. Kallio JP, Hirvikoski P, Helin H, Luukkaala T, Tammela TL, Kellokumpu-Lehtinen P and Martikainen PM: Renal Cell Carcinoma MIB-1, Bax and Bcl-2 expression and prognosis. J Urol 172: 2158-2161, 2004.
45. Mejean A, Oudard S and Thiounn N: Prognostic factors of renal cell carcinoma. J Urol 169: 821-827, 2003.
46. Javidan J, Stricker HJ, Tampoli P, Amin MB, Peabody JO, Deshpande A, Menon M and Amin MB: Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 162: 1277-1281, 1999.
47. Giuliani L, Giberti C, Martorana G and Rovida S: Radical extensive surgery for renal cell carcinoma: long term results and prognostic factors. J Urol 143: 468-473, 1990.
48. Mickish GH: Lymphatic metastases in renal cell carcinoma. What is the value of operation and adjuvant therapy? Urologe A 38: 326-331, 1999.
49. Usubutun A, Uygur MC, Ayhan A, Toklu C, Sahin A, Ozen H and Ruacan S: Comparison of grading systems for estimating the prognosis of renal cell carcinoma. Int Urol Nephrol 30: 391-397, 1998.